European Heart Journal vs JAMA Oncology: Which Journal Should You Choose?

EHJ asks whether the paper matters to cardiologists. JAMA Oncology asks whether the paper matters to oncologists.

That's the whole submission decision.

If the manuscript depends on cardiovascular risk frameworks, ESC relevance, imaging logic, or cardiology-facing outcomes interpretation, EHJ usually becomes the better home. If the manuscript depends on cancer care delivery, oncology outcomes, prevention, or broad clinical-oncology reasoning, JAMA Oncology usually becomes the better home.

EHJ wins when the cardio-oncology paper is fundamentally a cardiovascular paper.

That usually means:

• cardiotoxicity monitoring and management
• heart-failure or arrhythmia consequences after therapy
• cardiovascular surveillance studies
• imaging or registry work whose practical users are cardiologists

EHJ's editorial guidance repeatedly emphasize broad cardiology consequence, not only narrow subspecialty interest.

JAMA Oncology wins when the paper is fundamentally an oncology paper.

That includes:

• oncology outcomes studies with important cardiovascular dimensions
• cancer care-delivery or survivorship work where oncologists are the main audience
• prevention, treatment, or outcomes studies that change broad oncology thinking
• manuscripts whose strongest consequence still belongs inside oncology

JAMA Oncology's editorial guidance are especially clear that the journal wants papers that change prevention, diagnosis, treatment, outcomes, or management in cancer care.

EHJ's workflow is cardiology-first

EHJ submission's editorial guidance emphasizes ESC guidelines, European relevance, registries, and a cardiology-facing cover letter. That's a clue that a cardio-oncology paper belongs there only when the cardiovascular consequences are the real lead.

JAMA Oncology has a clear outcomes and care-delivery identity

fit's editorial guidance highlights cancer care delivery, outcomes research, and population-level oncology. That makes the journal a natural home for oncology-led cardio-oncology studies that are really about how cancer care should change.

EHJ is more comfortable with cardiology-native framing

Cardiology language, cardiovascular endpoints, and specialist surveillance logic are expected there.

JAMA Oncology is more comfortable with oncology-native framing

If the manuscript is fundamentally about cancer management and oncology consequences, that's a strength there, not a weakness.

• the paper is fundamentally cardiovascular
• cardiologists are the main audience
• surveillance, cardiovascular outcomes, or ESC relevance are central
• the manuscript becomes stronger when written for cardiology readers

That's the EHJ lane.

• the paper is fundamentally oncology-led
• oncologists are the main audience
• cancer outcomes, care delivery, or broad oncology consequence is central
• the manuscript becomes stronger when written for oncology readers

That's the JAMA Oncology lane.

This isn't a simple prestige cascade.

A paper rejected by EHJ does not automatically become a JAMA Oncology paper, and vice versa.

The cascade only works when the first journal saw the manuscript as belonging more naturally to the other specialty.

That can happen when:

• the paper sits at the cardio-oncology boundary
• the methods are strong
• the question matters to both fields
• the first journal judged that the primary readership was actually the other specialty

It doesn't work when the study is simply too narrow or too weak for either field-leading journal.

EHJ punishes papers that are too oncology-defined

If the cardiovascular consequence feels secondary to the cancer story, EHJ gets harder quickly.

JAMA Oncology punishes papers that are too cardiology-defined

If the main action belongs to cardiologists and the oncology consequences are mostly context, JAMA Oncology gets harder quickly.

EHJ punishes narrow cardiovascular consequence

The journal still wants broad cardiology significance, not only a decent cardio-oncology study.

JAMA Oncology punishes narrow oncology consequence

The paper still has to matter to a broad oncology audience, not just a tiny overlap between two specialties.

Cardiotoxicity surveillance and cardiovascular outcomes

These are usually cleaner EHJ papers when the goal is to change cardiovascular practice.

Cancer care-delivery and survivorship studies

These are often cleaner JAMA Oncology papers when the main practical readers are oncologists.

Registry and cohort analyses

The key question is whether the paper is fundamentally about cancer care or cardiovascular management. That usually tells you the right target.

Supportive care and long-term risk work

This category can go either way, but only if the manuscript is honest about which field must act first.

A strong EHJ first page makes the cardiovascular consequence obvious immediately. The reader should understand why cardiologists need this paper now.

A strong JAMA Oncology first page makes the oncology consequence obvious immediately. The reader should understand why oncologists need this paper now.

If the manuscript tries to do both equally, it may still be undecided about its real audience.

Ask which sentence fits the manuscript better:

• "this changes what cardiologists should do or think" points toward European Heart Journal
• "this changes what oncologists should do or think" points toward JAMA Oncology

That sentence is often the cleanest submission test.

At the cardio-oncology boundary, the wrong readership can flatten a strong paper. A study that's perfect for cardiologists can look too supportive for oncologists. A study that's perfect for oncologists can look only indirectly actionable for cardiologists.

That's why audience clarity matters more than brand reflexes in this comparison.

It also protects the paper from a weaker first editorial read. When the opening page is written for the wrong field, even good evidence can look less decisive than it really is.

Send to European Heart Journal first if:

1. the paper is fundamentally cardiovascular
2. cardiologists are the readers who most need it
3. ESC-facing relevance or cardiovascular management is central
4. the paper gets stronger when written for cardiology

Send to JAMA Oncology first if:

1. the paper is fundamentally oncology-led
2. oncologists are the readers who most need it
3. cancer outcomes, care delivery, or broad oncology consequence is central
4. the paper gets stronger when written for oncology

That is also why the safer strategy is usually to write the cover letter for the audience that will understand the claim fastest. If that audience is narrower, you usually shouldn't hide from that. You should submit to the journal that can judge the paper on the right terms the first time.